Methylprednisolone Recruiting Phase 2 Trials for de Novo Myelodysplastic Syndrome / Myelodysplastic Syndrome / Aplastic Anemia / Previously Treated Myelodysplastic Syndromes / Leukemias Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01624805Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome